Results 261 to 270 of about 650,104 (308)

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Steroidogenesis in castration-resistant prostate cancer

Urologic Oncology: Seminars and Original Investigations, 2023
Castration resistance is in part attributable to aberrant activation of androgen receptor (AR) signaling by the intracrine activation of androgen precursors derived from adrenal glands. To overcome this, novel AR pathway inhibitors (ARPIs) that suppress androgen synthesis by CYP17 inhibition or AR activation by antiandrogen effects have been developed.
Masaki Shiota, Satoshi Endo, Leandro Blas, Naohiro Fujimoto, Masatoshi Eto   +4 more
openaire   +2 more sources

Management of Patients with Castration-Resistant Disease

Hematology/Oncology Clinics of North America, 2013
The medical management of men with castration-resistant prostate cancer (CRPC) has changed dramatically in the last decade. Men can now access several agents developed to extend survival, delay morbidity caused by complications, and preserve quality of life.
Carmel, Pezaro, Aurelius, Omlin, David, Lorente, Johann, de Bono   +3 more
openaire   +2 more sources

Overcoming castration resistance in prostate cancer

Current Opinion in Urology, 2012
Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao, Alexander C, Small, Matthew D, Galsky, William K, Oh   +3 more
openaire   +2 more sources

The hallmarks of castration-resistant prostate cancers

Cancer Treatment Reviews, 2015
Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan.
Maria, Katsogiannou, Hajer, Ziouziou, Sara, Karaki, Claudia, Andrieu, Marie, Henry de Villeneuve, Palma, Rocchi   +5 more
openaire   +2 more sources

Immunotherapy for Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2012
The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire   +2 more sources

Castration-Resistant Prostate Cancer

Urologic Clinics of North America, 2017
Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Kelly Stratton, Michael Cookson
openaire   +2 more sources

Resistance to Castration – Resistance to Drugs

2013
Up to 70 % of newly diagnosed patients with advanced prostate cancer (PCa) will progress to castration-resistant prostate cancer (CRPC) and, in most cases (from 50 to 70 %), will develop hematogenous bone metastasis. Once PCa cells spread to the skeleton, cancer-related death becomes inevitable, with a death burden of more than 28,000 cases in 2012, in
openaire   +2 more sources